|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
April 2007FeaturesCover Story Coverage With Evidence Development: Private Payers Are WatchingA middle ground between unlimited coverage and no coverage at all, CED wasn’t developed with biologic therapies in mind. But healthcare players and payers are watching CED’s application carefully, as well as its effect on coverage and drug development. Drug Development Aptamers: The New Frontier In Drug Development?Often called chemical antibodies, aptamers are poised to take on the monoclonal antibodies in therapeutics, diagnostics, and drug development. Stability, low toxicity and immunogenicity, and, perhaps, a higher safety profile — not to mention low-cost advantages — are drawing the attention of big pharma and biotech. Business The Price Is Right......But is the drug? Perception plays a big role when any product competes on cost. The same is true for two biologic oncology therapies. To payers, the highest value doesn’t always match up with the lowest price. Policy Health Technology Assessment in Canada and the United States: the Case of BiologicsThe authors examine the Canadian process for health technology assessment and make the case that biologic healthcare applications would be diffused more effectively in the United States were a similar system here. Leading Edge The Changing HIV/AIDS Landscape: Where Do Biologics Fit In?Although no one is close to advancing a cure or preventive treatment, new antivirals, vaccines, and gene therapies in development may help to improve and lengthen the lives of patients living with HIV and AIDS. DepartmentsOpeners Patience Is Bitter, Its Fruit Is SweetPatience, primates, and a power grip. Editorial MANA From Heaven
David B. Nash, MD, MBA Washington Watch The Unpredictable Path from Group to Individual PoliciesHow could the Bush benefit plan affect utilization of biologic therapies? Diagnostics and Devices A Drop of Blood To Nip Disease in the BudA new emphasis on genotyping. Drug Track Approvals, FDA Actions, Clinical Trials
Michael D. Dalzell Biotech Business Payment Issues Stunt Markets for Crohn’s and Psoriasis TherapiesThird-party payer techniques stunt Crohn’s and psoriasis markets. Trends BIO: Part D Drug Costs Show the Market WorksAn effort to thwart drug-price controls. |
|||||